MiR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma

Pan，Xiang2; He，Tao3; Peng，Xiqi1,4; Li，Hang1; Zhang，Fangting1; Lai，Yongqing1

2020

American Journal of Translational Research   影响因子和分区

1943-8141

1943-8141

Objective: The aim of this study was to investigate the function and prognostic value of miR-638 in renal cell carcinoma (RCC). Methods: Expression of miR-638 in RCC tissues and corresponding noncancerous tissues were examined by reverse transcription quantitative polymerase chain reaction (RT-qPCR). To explore the effects of miR-638 on cell migration, invasion, viability, and apoptosis of RCC cells, wound scratch, transwell, MTT, CCK-8, and flow cytometry assays were performed. Kaplan-Meier and Cox regression analyses were used to evaluate the relationship between miR-638 expression and prognosis of RCC patients. Potential target genes of miR-638 were predicted and validated via multiple bioinformatics analyses. Results: miR-638 was upregulated in RCC tissues when compared with corresponding noncancerous tissues (P < 0.05). Upregulation of miR-638 expression by transfection with a synthetic miR-638 mimic promoted cell migration, invasion, and viability and suppressed cell apoptosis. Moreover, Kaplan-Meier analysis revealed that upregulation of miR-638 associated with shorter overall survival (OS; P = 0.001). Cox univariate and multivariate regression analysis suggested that miR-638 expression is an independent predictive factor for the prognosis of RCC patients (P = 0.004). KCNQ1, DNAJC6, and PNP were identified as potential target genes of miR-638. Conclusions: The results of this study demonstrated that miR-638 functions as an oncogene in RCC and has the potential to be a prognostic biomarker for RCC.

Biomarkers Microrna Mir-638 Oncogene Renal cell carcinoma

英语

其他

2-s2.0-85089314547

Scopus

1.Guangdong and Shenzhen Key Laboratory of Male Reproductive Medicine and Genetics,Peking University Shenzhen Hospital,Shenzhen, Guangdong,518036,China
2.Department of Urology,Affiliated Hospital of Yangzhou University,Yangzhou University,Yangzhou, Jiangsu,225000,China
3.Department of Urology,Shenzhen People's Hospital,Second Clinical Medical College,Jinan University; The First Affiliated Hospital,Southern University of Science and Technology,Shenzhen, Guangdong,518020,China
4.Shantou University Medical College,Shantou, Guangdong,515041,China

Pan，Xiang,He，Tao,Peng，Xiqi,et al. MiR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma[J]. American Journal of Translational Research,2020,12(7):3645-3659.

Pan，Xiang,He，Tao,Peng，Xiqi,Li，Hang,Zhang，Fangting,&Lai，Yongqing.(2020).MiR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma.American Journal of Translational Research,12(7),3645-3659.

Pan，Xiang,et al."MiR-638 acts as an oncogene and predicts poor prognosis in renal cell carcinoma".American Journal of Translational Research 12.7(2020):3645-3659.